-
<![CDATA[Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis]]>
18 Dec 2025 12:30 GMT
… other signaling pathways fundamental to psoriasis, may provide patients with significant … other cytokine pathways implicated in psoriasis pathogenesis. According to Takeda, the … skin for patients with plaque psoriasis.” However, translating trial efficacy …
-
Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris
18 Dec 2025 12:30 GMT
… frequency below 1%.1 About Psoriasis Psoriasis is a chronic, immune- … worldwide, are affected by psoriasis.6 Chronic plaque psoriasis (psoriasis vulgaris) is the … ;cdnpsoriasisguidelines.pdf
Canadian Dermatology Association. Psoriasis. Accessed May 21, 2025. …
-
Thérapeutique Knight annonce l’obtention de l’autorisation de Santé Canada pour WYNZORA® pour le traitement du psoriasis vulgaris
18 Dec 2025 12:30 GMT
… %.1 À propos du psoriasis Le psoriasis est une maladie inflammatoire … touchés par le psoriasis.6 Le psoriasis en plaques chronique (psoriasis vulgaris) constitue … DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project …
-
Tildrakizumab Effective and Safe in Patients With Psoriasis
18 Dec 2025 13:00 GMT
… with moderate-to-severe plaque psoriasis.
METHODOLOGY:
Researchers conducted a multicentre … tildrakizumab.
Efficacy was evaluated using Psoriasis Area and Severity Index (PASI … option for moderate-to-severe psoriasis in routine clinical practice, even …
-
Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
18 Dec 2025 15:18 GMT
… . More than half the plaque psoriasis patients across the studies showed … would join a crowded plaque psoriasis market featuring well-established oral … injectable drugs for treating plaque psoriasis, in which red, scaly patches …
-
Takeda’s psoriasis pill developed with AI assistance succeeds in trials
18 Dec 2025 10:39 GMT
… announced that its oral psoriasis drug zasocitinib proved safe … the small but growing oral psoriasis treatments — long a … Jefferies Japan. The global psoriasis treatment market, valued at … firm Fortune Business Insights. Psoriasis is a chronic autoimmune …
-
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
18 Dec 2025 08:57 GMT
… other signaling pathways fundamental to psoriasis, may provide patients with … March 31, 2026.
About Plaque Psoriasis
Psoriasis is a chronic immune-mediated … Deucravacitinib in Adults With Plaque Psoriasis. ClinicalTrials.gov Identified: NCT06973291. …
-
Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel
17 Dec 2025 18:32 GMT
… Investigator Global Assessment (IGA), the Psoriasis Activity and Severity Index (PASI … ), the simplified psoriasis index, the dermatology life quality … success of photodynamic therapies in psoriasis, and is well tolerated, potentially …
-
<![CDATA[Phase 2a Results Demonstrate Safety and Efficacy of SGX302 Gel in Mild-to-Moderate Psoriasis]]>
17 Dec 2025 16:20 GMT
… and Severity Index (PASI), simplified psoriasis index, Dermatology Life Quality Index … demonstrated responses in patients with psoriasis, providing a rationale for continued … Patients with Mild-to-Moderate Psoriasis. News release. Soligenix. Published …
-
Antibodies Targeting Gasdermin E as a Potential Therapeutic Option for Psoriasis – A Pilot Study on a Mouse Model
17 Dec 2025 15:25 GMT
… therapeutic targets.
In general, psoriasis pathogenesis encompasses the interplay between … of apoptosis observed in the psoriasis pathogenesis.
Subsequent studies have … concentrations with clinicopathologic outcome in psoriasis. Dermatol Pract Concept. 2024 …